Pfizer: I'm Still Expecting A Massive Rebound [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
The Seagen integration has doubled Pfizer's oncology pipeline to 60 programs, with the division on track to hit a $10 billion revenue target by 2030. PFE management anticipates a "steep hockey stick" launch for its obesity portfolio by 2028, targeting a significant share of the projected $200 billion GLP-1 market. Despite looming patent protection losses for Ibrance and Xtandi, aggressive cost-cutting and high-growth specialty launches are expected to stabilize PFE's long-term earnings profile. Trading at just 9x forward earnings with a generous 6.4% dividend yield, PFE stock offers a compelling 30% total return potential over the next 12–16 months. Looking for more investing ideas like this one? Get them exclusively at Beyond the Wall Investing. Learn More » georgeclerk/iStock Unreleased via Getty Images PFE's Strength Is Only Getting Started After years of covering Pfizer Inc. ( PFE ) stock, I'm glad to see PFE stock finally moving upwards despite the existing LOE ris
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer aims for wider use of PARP drug in prostate cancer with new data [Yahoo! Finance]Yahoo! Finance
- The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients [Fortune]Fortune
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerBusiness Wire
- PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push [Yahoo! Finance]Yahoo! Finance
- Contraceptives Drugs Market Size to Reach USD 46.24 Billion by 2035; Rising Awareness of Family Planning Driving Market Growth – SNS Insider [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- 3/12/26 - Form DEFA14A
- PFE's page on the SEC website